Tag: Ombitasvir
-
Study Suggests Alternative to Common HCV Treatment with Equally High SVR, No PPI Modification Needed
American College of Gastroenterology / Posts / Uncategorized / Study Suggests Alternative to Common HCV Treatment with Equally High SVR, No PPI Modification NeededPoster 413 Efficacy of Ombitasvir/Paritaprevir/ and Dasabuvir +/-Ribavirin in Patients Receiving Concomitant Acid-Reducing Agents in Phase 3 Trials Author Insight…
-
Study Suggests All-Oral Therapy for HCV G1 Patients is Highly Effective, Regardless of Race or Ethnicity
American College of Gastroenterology / Posts / Uncategorized / Study Suggests All-Oral Therapy for HCV G1 Patients is Highly Effective, Regardless of Race or EthnicityOral 65 High SVR Rates Among US Patients Regardless of Race or Ethnicity in HCV GT1 Patients Receiving the Label-Recommended…
-
ACG 2014 Virtual Press Briefing: Hepatitis C
American College of Gastroenterology / Posts / Uncategorized / ACG 2014 Virtual Press Briefing: Hepatitis CThis year the College offers a series of pre-recorded virtual press briefings which feature the insights of leading gastroenterology experts…
-
Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT -450/R/Ombitasvir, Dasabuvir and Ribavirin
American College of Gastroenterology / Posts / Uncategorized / Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT -450/R/Ombitasvir, Dasabuvir and RibavirinOral 5: Normalization of Liver-Related Laboratory Parameters in HCV Genotype 1-Infected Patients With Cirrhosis After Treatment With ABT-450/R/Ombitasvir, Dasabuvir and…
-
SVR12 of 99% Achieved With a Ribavirin-Free Regiment of ABT-450r Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected Patients
American College of Gastroenterology / Posts / Uncategorized / SVR12 of 99% Achieved With a Ribavirin-Free Regiment of ABT-450r Ombitasvir and Dasabuvir in HCV Genotype 1b-Infected PatientsOral 4: SVR12 (sustained virologic response 12 weeks post-treatment) of 99% Achieved With a Ribavirin-Free Regiment Author Insight from Andreas…